Gossamer Bio
About Gossamer Bio
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
YEAR FOUNDED:
2018
LEADERSHIP:
Founders and CEO: Faheem Hasnain
Founder and COO: Sheila Gujrathi, M.D
115 articles about Gossamer Bio
-
Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update
8/9/2022
Gossamer Bio today announced its financial results for the second quarter ended June 30, 2022 and provided a business update.
-
Gossamer Bio sold shares of its common stock to pave its runway through mid-2024 while Teva and AbbVie reach deals in opioid settlements.
-
Gossamer Bio Announces $120 Million Private Placement Financing
7/13/2022
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced today it has agreed to sell approximately 16.6 million shares of its common stock to a select group of institutional and accredited investors in a private placement, at a price per share of $7.21.
-
Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH
6/9/2022
Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH.
-
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update
5/10/2022
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the first quarter ended March 31, 2022 and provided a business update.
-
Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update
4/25/2022
Gossamer Bio, Inc. today announced topline results from its Phase 2 SHIFT-UC Study clinical trial studying GB004 in patients with mild-to-moderate active ulcerative colitis (UC).
-
Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update
3/3/2022
Gossamer Bio, Inc. announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.
-
Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022
2/28/2022
Gossamer Bio, Inc. today announced that it will report its fourth quarter and full-year 2021 financial results on Thursday, March 3, 2022.
-
The San Diego-based immunology company is locating and developing molecules where the mechanism of action has either been proven or makes sense.
-
Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update
11/8/2021
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced its financial results for the third quarter of 2021 and provided a corporate update.
-
Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
11/2/2021
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its third quarter 2021 financial results on Monday, November 8, 2021.
-
Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208
10/11/2021
Gossamer Bio, Inc. today announced the addition of two CNS-penetrant Bruton’s tyrosine kinase (BTK) inhibitors to its product candidate pipeline.
-
Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021
10/7/2021
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Monday, October 11, 2021, at 2:30 pm ET.
-
Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role
9/21/2021
Gossamer Bio, Inc. today announced that, Bryan Giraudo has been appointed Chief Operating Officer, in addition to his continued role as Chief Financial Officer.
-
Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
8/9/2021
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced its financial results for the second quarter of 2021 and provided a corporate update.
-
Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021
8/2/2021
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its second quarter 2021 financial results on Monday, August 9, 2021.
-
Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn’s and Colitis Organisation
7/7/2021
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced that it will present data related to GB004 at the 2021 Virtual Congress of the European Crohn’s and Colitis Organisation, to be held virtually from July 2-3 and 8-10.
-
Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer
6/21/2021
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that, Richard Aranda, M.D., previously Senior Vice President and Head of Clinical Development, will be promoted to Chief Medical Officer
-
Gossamer Bio Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of Directors
6/14/2021
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the appointment of Sandra Milligan, M.D., J.D., to its Board of Directors.
-
Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
5/6/2021
– Seralutinib and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively – – Cash, cash equivalents and marketable securities totaled $453 million as of March 31, 2021 –